Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:BNENASDAQ:PHAR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNEBlue Horizon BNE ETF$21.69+0.6%$22.06$19.53▼$27.62$4.88M1.32598 shs1,215 shsPHARPharming Group$9.69-2.3%$10.96$9.27▼$16.71$650.30M0.162,593 shs525 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNEBlue Horizon BNE ETF+0.64%-0.73%-3.66%+2.60%-12.34%PHARPharming Group-0.80%-2.84%-11.98%-17.33%-7.29%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNEBlue Horizon BNE ETFN/AN/AN/AN/AN/AN/AN/AN/APHARPharming Group2.4797 of 5 stars3.55.00.00.02.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNEBlue Horizon BNE ETF0.00N/A$22.935.71% UpsidePHARPharming Group3.00Buy$37.00281.84% UpsideCurrent Analyst RatingsLatest BNE, COI, PHAR, and EEG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNEBlue Horizon BNE ETFN/AN/AN/AN/AN/AN/APHARPharming Group$245.32M2.65$0.09 per share102.60$3.26 per share2.97Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNEBlue Horizon BNE ETFN/AN/A13.26∞N/AN/AN/AN/AN/APHARPharming Group-$10.55M-$0.14N/AN/AN/A-4.13%-4.53%-2.14%5/9/2024 (Estimated)Latest BNE, COI, PHAR, and EEG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023PHARPharming Group$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNEBlue Horizon BNE ETF$0.060.28%N/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNEBlue Horizon BNE ETFN/AN/AN/APHARPharming Group0.624.063.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNEBlue Horizon BNE ETFN/APHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipBNEBlue Horizon BNE ETFN/APHARPharming Group2.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBNEBlue Horizon BNE ETFN/A225,000N/ANot OptionablePHARPharming Group33267.11 million65.72 millionNot OptionableBNE, COI, PHAR, and EEG HeadlinesSourceHeadlinePharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00marketbeat.com - April 22 at 1:31 PMPharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?zacks.com - April 22 at 6:31 AMPharming Group (NASDAQ:PHAR) Sees Large Volume Increaseamericanbankingnews.com - April 21 at 4:44 AMPharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35americanbankingnews.com - April 20 at 4:40 AMPharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025finanznachrichten.de - April 19 at 4:05 PMPharming Group (NASDAQ:PHAR) Sees Strong Trading Volumemarketbeat.com - April 19 at 1:37 PMPharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029finanznachrichten.de - April 18 at 6:18 PMPharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025finance.yahoo.com - April 18 at 8:17 AMPharming Group (NASDAQ:PHAR) Stock Price Down 6.8%marketbeat.com - April 15 at 1:55 PMPharming Group (NASDAQ:PHAR) Shares Gap Down to $11.30americanbankingnews.com - April 14 at 2:32 AMPharming Group (NASDAQ:PHAR) Shares Down 5% marketbeat.com - April 9 at 3:19 PMEnrollment completed for trial of drug to treat children with rare primary immunodeficiencyoutsourcing-pharma.com - April 8 at 8:50 AMPharming announces completion of enrollment in pediatric clinical trial of leniolisibfinance.yahoo.com - April 8 at 1:34 AMPharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96marketbeat.com - April 4 at 6:21 PMPharming Group announces the filing of its 2023 Annual Report and Form 20-Ffinance.yahoo.com - April 4 at 1:14 AMUber to pay $178 million in Australia taxi class action settlementmsn.com - March 18 at 3:45 AMPharming reports Q4 resultsmsn.com - March 15 at 7:46 PMPharming Group N.V. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - March 14 at 9:06 AMPharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14finanznachrichten.de - February 29 at 6:26 AMPharming Group N.V. (PHGN.F)finance.yahoo.com - February 20 at 3:10 PMPharming Group N.V.: Pharming Group to participate in February investor conferencesfinanznachrichten.de - February 8 at 3:55 AMPharming Group to participate in February investor conferencesfinance.yahoo.com - February 8 at 3:55 AMAstria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readoutseekingalpha.com - February 5 at 12:52 AMPharming Group: Strong Buy Rating on Robust Revenue Growth and Promising Clinical Pipeline Expansionmarkets.businessinsider.com - January 8 at 7:31 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesBreakout Alert: Coinbase's Consolidation Is About To EndApril 12, 2024 9:45 AMView Breakout Alert: Coinbase's Consolidation Is About To EndAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentApril 3, 2024 9:10 AMView Akebia Therapeutics Surges on FDA Approval for Anemia TreatmentCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? All In: Is MicroStrategy Overleveraging Its Future on Bitcoin? March 26, 2024 6:05 AMView All In: Is MicroStrategy Overleveraging Its Future on Bitcoin? Bitcoin Depot Falls Into Value Territory With Expansion UnderwayMarch 28, 2024 7:37 AMView Bitcoin Depot Falls Into Value Territory With Expansion UnderwayAll Headlines Company DescriptionsBlue Horizon BNE ETFNYSEARCA:BNEThe Blue Horizon BNE ETF (BNE) is an exchange-traded fund that is based on the Blue Horizon New Energy Economy 100 index. The fund tracks an equal-weighted index of global stocks that are perceived to benefit from a New Energy Economy. BNE was launched on Dec 8, 2020 and is managed by Blue Horizon.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
